10-14-03

PTO/SB/21 (08-03)

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	09/322,289
		Filing Date	May 28, 1999
		First Named Inventor	Schenk, Dale B.
		Art Unit	1647
		Examiner Name	Turner, Sharon L.
Total Number of Pages in This Submission	29	Attorney Docket Number	15270J-004740US

ENCLOSURES ***(Check all that apply)***

- ☒ Fee Transmittal Form (1 p., submitted in duplicate)
- ☐ Amendment/Reply
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Supplemental Information Disclosure Statement (5 pgs.) w/attached PTO/SB/08A (2 pgs.), PTO/SB/08B (7 pgs.), & Form PTO-1449 (4 pgs.)
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/ Incomplete Application
  - ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53
- ☐ Drawing(s)
- ☐ Petition
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s)
- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Group (**Appeal Notice, Brief, Reply Brief**)
- ☒ Other Enclosure(s) *(please identify below)*:
  Return Postcard

RECEIVED OCT 17 2003 TECH CENTER 1600/2900

Remarks

The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

*The following papers are also attached to the Supplemental Information Disclosure Statement: Supplemental Information Disclosure Statement (2 pgs.) w/ attached Form PTO-1449 (4 pgs.) submitted August 25, 2000; and, PAIR Report (3 pp.).

** Citing ref. nos. 3-4, 6-8, 10, 12, 14-16, 18-20, 23-28, 31, 35, 37-43, 45-46, 48-51, 53-57, 63-66, 70-71, 73-77, 79-86, 88-89, 91, 93-98, 101-102, 105-108, 110, 115-116, 118, 121-125, 127-129, 131, 136-137, 139, 143, 147, 152-155, 157, 162, 165-166, 168-169 and 171, which are not included in the "Total Number of Pages in This Submission."

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual	Townsend and Townsend and Crew LLP Rosemarie L. Celli Reg. No. 42,397
Signature	Rosemarie L. Celli
Date	October 9, 2003

CERTIFICATE OF MAILING

Express Mail Label: EV 323 381 067 US

I hereby certify that this correspondence is being deposited with the United States Postal Service with "Express Mail Post Office to Address" service under 37 CFR 1.10 on this date October 9, 2003 and is addressed to:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Typed or printed name	Daniel Miranda		
Signature		Date	October 9, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

60056562 v1

PTO/SB/17 (05-03)
Approved for use through 04/30/2003. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

FEE TRANSMITTAL for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT ($) 180

Complete if Known	
Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Schenk, Dale B.
Examiner Name	Sharon L. Turner
Art Unit	1647
Attorney Docket No.	15270J-004740US

METHOD OF PAYMENT *(check all that apply)*

☐ Check ☐ Credit Card ☐ MoneyOrder ☐ Other ☐ None

☒ Deposit Account:

Deposit Account Number: 20-1430

Deposit Account Name: Townsend and Townsend and Crew LLP

The Commissioner is authorized to: *(check all that apply)*

☒ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s) during the pendency of this application

☐ Charge fee(s) indicated below, **except for the filing fee** to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code	Large Entity Fee ($)	Small Entity Fee Code	Small Entity Fee ($)	Fee Description	Fee Paid
1001	750	2001	375	Utility filing fee	
1002	330	2002	165	Design filing fee	
1003	520	2003	260	Plant filing fee	
1004	750	2004	375	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1) ($)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

			Extra Claims	Fees from below	Fee Paid
Total Claims		-** =		X =	
Independent Claims		-** =		X =	
Multiple Dependent				X =	

Large Entity Fee Code	Large Entity Fee ($)	Small Entity Fee Code	Small Entity Fee ($)	Fee Description
1202	18	2202	9	Claims in excess of 20
1201	84	2201	42	Independent claims in excess of 3
1203	280	2203	140	Multiple dependent claim, if not paid
1204	84	2204	42	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) ($)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code	Large Entity Fee ($)	Small Entity Fee Code	Small Entity Fee ($)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	410	2252	205	Extension for reply within second month	
1253	930	2253	465	Extension for reply within third month	
1254	1,450	2254	725	Extension for reply within fourth month	
1255	1,970	2255	985	Extension for reply within fifth month	
1401	320	2401	160	Notice of Appeal	
1402	320	2402	160	Filing a brief in support of an appeal	
1403	280	2403	140	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive – unavoidable	
1453	1,300	2453	650	Petition to revive – unintentional	
1501	1,300	2501	650	Utility issue fee (or reissue)	
1502	470	2502	235	Design issue fee	
1503	630	2503	315	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Petitions related to provisional applications	
1806	180	1806	180	Submission of Information Disclosure Stmt	180
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	750	2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))	
1810	750	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))	
1801	750	2801	375	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid **SUBTOTAL (3)** ($)180

SUBMITTED BY				Complete *(if applicable)*	
Name (Print/Type)	Rosemarie L. Celli	*Registration No. (Attorney/Agent)*	42,397	*Telephone*	650-326-2400
Signature	Rosemarie L. Celli			*Date*	October 9, 2003

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.** 60057252 v1

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

"Express Mail" Label No. EV 323 381 067 US
Date of Deposit October 9, 2003

PATENT
Attorney Docket No.: 15270J-004740US
Client Reference No.: 209-US-CIP5

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TOWNSEND and TOWNSEND and CREW LLP

By: _____

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Schenk, Dale B.

Application No.: 09/322,289

Filed: May 28, 1999

For: PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE

Examiner: Turner, Sharon L.

Art Unit: 1647

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

The references cited on the attached Form PTO-1449 ("1449") are also being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom. The 1449, Supplemental IDS Return Receipt Postcard, all of which are attached hereto, were submitted via first class mail on August 25, 2000. According to PAIR, the August 25, 2000 submission has not been entered. (*See* the attached PAIR report generated October 8, 2003.) The 1449 submitted August 20, 2000 used a two letter code to identify the references. The 1449 submitted herewith for consideration is a modified version of the August 25, 2000 submission, *i.e.*, the two letter code has been redacted and the references are identified by number.

Applicant also cites commonly owned copending applications directed to related subject matter:

09/201,430 filed 11/30/98;
09/497,553 filed 02/03/00;
09/724,477 filed 11/28/00;
09/723,927 filed 11/28/00;
09/724,762 filed 11/28/00;
09/724,102 filed 11/28/00;
09/724,489 filed 11/28/00;
09/322,289 filed 05/28/99;
09/723,713 filed 11/27/00;
09/723,760 filed 11/27/00;
09/724,319 filed 11/27/00;
09/723,384 filed 11/27/00;
09/724,495 filed 11/27/00;
10/429,216 filed 05/30/03;

09/580,015 filed 05/26/00;

09/724,940 filed 11/28/00;

09/724,961 filed 11/28/00;

09/580,018 filed 05/26/00;

09/724,552 filed 11/28/00;

09/723,544 filed 11/28/00;

09/724,273 filed 11/28/00;

09/724,551 filed 11/28/00;

09/724,288 filed 11/28/00;

09/580,019 filed 05/26/00;

09/723,765 filed 11/28/00;

09/724,291 filed 11/28/00;

09/204,838 filed 12/03/98;

09/724,929 filed 11/28/00;

09/585,817 filed 06/01/00;

09/724,567 filed 11/28/00;

09/724,575 filed 11/28/00;

09/724,953 filed 11/28/00;

09/724,570 filed 11/28/00;

09/585,656 filed 06/01/00;

09/723,766 filed 11/27/00;

09/723,725 filed 11/27/00;

09/579,690 filed 05/26/00;

09/979,701 filed 03/13/01 (U.S. National Stage of PCT/US00/14810 filed 05/26/00);

09/979,952 filed 04/04/02 (U.S. National Stage of PCT/US00/15239 filed 06/01/00);

and,

09/980,568 filed 03/12/02 (U.S. National Stage of PCT/US00/15302 filed 06/01/00).

Applicant also cites the following copending applications directed to related subject matter but subject to different assignment:

10/010,942 filed 12/06/01;

10/232,030 filed 08/30/02;

10/388,389 filed 03/12/03;

60/444,150 filed 02/01/03;

10/388,214 filed 03/12/03; and,

60/474,654 filed 05/30/03.

Applicant further cites the following commonly owned abandoned applications directed to related subject matter:

60/067,740 filed 12/02/97;

60/080,970 filed 04/07/98;

60/067,219 filed 12/03/97;

60/079,697 filed 03/27/98;

09/724,921 filed 11/28/00;

60/137,010 filed 06/01/99;

60/137,047 filed 06/01/99; and,

60/136,655 filed 05/28/99.

Applicant also cites the following abandoned application directed to related subject matter but subject to different assignment:

60/251,892 filed 12/06/00; and,

60/363,751 filed 03/12/02.

Applicant points out that the following applications are now commonly assigned but were previously subject to different assignment than the present application:

60/067,219 filed 12/03/97;

60/079,697 filed 03/27/98;

09/204,838 filed 12/03/98;

09/724,921 filed 11/28/00; and,

09/724,929 filed 11/28/00.

The Assignee of the instant application is a licensee of U.S. Patent 5,688,651, which is directed in part to subject matter related to the instant application. U.S. Patent No. 5,688,651 is now undergoing examination reissue as Application No. 09/441,140. U.S. Patent No. 5,688,651 is submitted herewith at cite number 16. US. Application No. 09/441,140 was cited as cite no. 283 in the Supplemental IDS filed June 2, 2003.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

Please charge the IDS fee of $180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Rosemarie L. Celli

Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
RLC:crf

60055883 v1

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 9

Complete if Known	
Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Sharon L. Turner
Attorney Docket Number	15270J-004740US

U.S. PATENT DOCUMENTS

Examiner	Cite No.[1]	Document Number Number Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	360	2003/0073655 A1	04-17-2003	Chain	
	370	2003/0068325 A1	04-10-2003	Wang	
	378	2002/0197258 A1	12-26-2003	Ghanbari et al.	
	366	2002/0187157 A1	12-12-2002	Jensen et al.	
	377	2002/0168377 A1	11-14-2002	Schaetzl	
	395	2002/0160394 A1	10-31-2002	Wu	
	379	2002/0132268 A1	09-19-2002	Chang et al.	
	365	2002/0133001 A1	09-19-2002	Gefter et al.	
	362	2002/0094335 A1	07-18-2002	Chalifour et al.	
	376	2002/0086847 A1	07-04-2002	Chain	
	405	6,399,314 B1	06-04-2002	Krishnamurthy	
	267	6,294,171 B2	09-25-2001	McMichael	
	381	2001/0021769 A1	09-13-2001	Prusiner	
	401	6,284,533 B1	09-04-2001	Thomas	
	234	6,284,221 B1	09-04-2001	Schenk, et al.	
	300	2001/0018053 A1	08-30-2001	McMichael	
	230	6,262,335 B1	07-17-2001	Hsiao et al.	
	231	6,114,133	09-05-2000	Seubert et al.	
	221	5,989,566	11-23-1999	Cobb et al.	
	382	5,846,533	12-08-1998	Prusiner	
	380	5,750,361	05-12-1998	Prusiner et al.	
	373	5,721,130	02-24-1998	Seubert et al.	
	403	5,464,823	11-07-1995	Lehrer et al.	
	284	5,231,170	07-27-1993	Averback	
	402	4,713,366	12-15-1987	Stevens	

Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] **Applicant's** unique citation designation number **(optional).** [2] Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 9

Complete if Known	
Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Sharon L. Turner
Attorney Docket Number	15270J-004740US

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		Country Code[3]	Number[4]	Kind Code[5] (if known)				
	294	WO	01/62801	A2	08-30-2001			
	301	WO	01/62284	A2	03-01-2000			
	298	WO	01/42306	A2	06-14-2001			
	243	WO	01/39796	A2	06-07-2001			
	240	WO	00/43039	A1	07-27-2000			
	383	WO	97/10505	A1	03-20-1997			
	227	WO	95/11008	A2	04-27-1995			

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] **Applicant's** unique citation designation number **(optional).** [2] Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 9

Complete if Known	
Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Sharon L. Turner
Attorney Docket Number	15270J-004740US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	391	AGUZZI et al., "Prion research: the next frontiers," Nature, 389:795-798 (1997).	
	393	AKIYAMA et al., "Inflammation and Alzheimer's disease," Neurobiology of Aging, 21:383-421 (2000).	
	372	AKIYAMA et al., "Occurrence of the Diffuse Amyloid β-Protein (Aβ) Deposits With Numerous Aβ-Containing Glial Cells in the Cerebral Cortex of Patients With Alzheimer's Disease," Glia, 25:324-331 (1999).	
	228	BARROW et al., "Solution Conformations and aggregational Properties of Synthetic Amyloid Beta-Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra," J. Mol.Biol., 225(4): 1075-1093 (1992).	
	239	BEASLEY, "Alzheimer's traced to proteins caused by aging," Reuters, April 20, 2001 7:56 PM ET.	
	404	BENJAMINI and LESKOWITZ, from *IMMUNOLOGY A Short Course*, Second Edition, Chapter 4, Antibody Structure, pages 49-65, 1991, published by Wiley-Liss, Inc., New York, New York.	
	285	CAPUTO et al., "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," Clin. Neuropharm., 15:414A-414B (1992).	
	224	Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Thimerosal in Vaccines (Mercury in Plasma-Derived Products), web site contents found at : http://www.fda.gov/cber/vaccine/thimerosal.htm, last updated May 16, 2002.	
	266	CHAPMAN, "Model behavior," Nature, 408:915-916 (2000).	
	222	Chemical Abstract database, Abstract of "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals," Chemical Abstract database. (Publication date unknown.)	
	291	COLOMA et al., "Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor," Pharm. Res., 17:266-274 (2000).	
	286	CORDELL, B., "β-Amyloid formation as a potential therapeutic target for Alzheimer's disease," Ann. Rev. Pharmacol. Toxicol., 34:69-89 (1994).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE.
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 9

Complete if Known	
Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Sharon L. Turner
Attorney Docket Number	15270J-004740US

	287	COSTA et al., "Immunoassay for transthyretin variants associated with amyloid neuropathy," Scand. J. Immunol., 38:177-182 (1993).	
	293	DALY, et al., "Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's Disease brain," Life Sci., 63:2121-2131 (1998).	
	220	Dialog/Derwent, Abstract of WPI Acc No: 1997-054436/199706: Stable vaccine compsns. – comprise a macrocyclic lactone, a milbemycin, an avermectin, an antigen, a dispersing agent, an adjuvant, a water sol. organic solvent and saline or water, Derwent File 351: Derwent WPI database. (Publication date unknown.)	
	390	DIOMEDE et al., "Activation effects of a prion protein fragment [PrP-(106-126)] on human leucocytes," Biochem. J., 320:53-570 (1996).	
	363	DODART, "Immunotherapy for Alzheimer's disease: will vaccination work?" Trends in Molecular Medicine, 9(3):85-87 (2003).	
	288	DUMERY et al., "β-Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease," Pathol. Biol., 49:72-85 (2001).	
	225	Elan, "Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792," Press Release. (1/18/2002).	
	226	Elan, "Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration," Press Release (3/1/2002)	
	289	ESIRI, "Is an effective immune intervention for Alzheimer's disease in prospect?", Trends in Pharm, Sci., 22:2-3 (2001).	
	386	FRATUTSCHY et al., "Effects of injected Alzheimer β-amyloid cores in rat brain," PNAS, 88:8362-8366 (1991).	
	246	FRENKEL et al., "Generation of auto-antibodies towards Alzheimer's disease vaccination," Vaccine, 19:2615-2619 (2001).	
	245	FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β-amyloid peptide is essential for modulation of fibrillar aggregation," J. of Neuroimmunology, 95:136-142 (1999).	
	247	FRENKEL et al., "Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration," PNAS USA, 97:11455-11459 (2000).	

Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 9

Complete if Known	
Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Sharon L. Turner
Attorney Docket Number	15270J-004740US

	248	FRENKEL et al., "N-terminal EFRH sequence of Alzheimer's β-amyloid peptide represents the epitope of its anti-aggregating antibodies," J. of Neuroimmunology, 88:85-90 (1998).	
	244	FRENKEL, et al., "Modulation of Alzheimer's β-amyloid neurotoxicity by site-directed single chain antibody," J. of Neuroimmunology, 106:23-31 (2000).	
	249	FRIEDLAND, et al., "Neuroimaging of Vessel Amyloid in Alzheimer's Disease," in Cerebrovascular Pathology in Alzheimer's Disease, eds. de la Torre and Hachinski, New York Academy of Sciences, New York, New York (1997).	
	364	FURLAN et al., "Vaccination with amyloid-β peptide induces autoimmune encephalomyelitis in C57/BL6 mice," Brain, 126:285-291 (2003).	
	251	GARDELLA et al., "Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," Biochem. Biophys. Res. Comm., 173:1292-1298 (1990).	
	252	GEDDES, "N-terminus truncated β-amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease," Neurobiology of Aging, 20:75-79 (1999).	
	253	GIULIAN, et al., "The HHQK Domain of b-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," Journal of Biological Chem., 273:29719-29726 (1998).	
	388	GOLDFARB et al., "The Transmissible Spongiform Encephalopathies," Ann. Rev. Med., 46:57-65 (1995).	
	397	GOLDSTEINS et al., "Goldsteins et al., Éxposure of cryptic epitopes on transthyretin only in amypoid and in amyloidogenic mutants," PNAS, 96:3108-3113 (1999).	
	237	GORTNER, Outlines of Biochemistry, pp. 322-323, John Wiley & Sons, Inc., New York (1949).	
	254	GRUBECK-LOEBENSTEIN, et al., "Immunization with β-amyloid: could T-cell activation have a harmful effect?", TINS, 23:114 (2000).	
	241	HAASS et al. "Amyloid beta-peptide is produced by cultured cells during normal metabolism," Nature, 359(6393):322-5 (1992).	
	255	HARIGAYA, et al., "Modified amyloid β protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease," Biochem. Biophys. Res. Comm., 211:1015-1022 (1995).	

Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 9

Complete if Known	
Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Sharon L. Turner
Attorney Docket Number	15270J-004740US

	229	HAZAMA, et al., "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of Escherichia Coli Heat-Labile Enterotoxin and Interleukin-2", Immunology, Vol. 78: 643-649 (1993).	
	236	HILBICH et al., "Human and rodent sequence analogs of Alzheimer's amyloid βA4 share similar properties and can be solubilized in buffers of pH 7.4," Eur. J. Biochem., 201:61-69 (1991).	
	256	IKEDA, et al., "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti-β protein monoclonal antibody," Lab. Invest., 57:446-449 (1987).	
	374	JAKES et al., "Characterisation of an Antibody Relevant to the Neuropathology of Alzheimer Disease," Alzheimer Disease and Associated Disorders, 9(1):47-51, Raven Press, Ltd., New York (1995).	
	257	JEN, et al., "Preparation and purification of antisera against different regions or isoforms of b-amyloid precursor protein," Brain Research Protocols, 2:23-30 (1997).	
	371	JOHNSTONE et al., Nuclear and Cytoplasmic Localization of the β-Amyloid Peptide (1-43) in Transfected 293 Cells," Biochemical and Biophysical Research Communications, 220:710-718 (1996).	
	258	KIDA, et al., "Early amyloid-β deposits show different immunoreactivity to the amino- and carboxy-terminal regions of b-peptide in Alzheimer's disease and Down's syndrome brain," Neuroscience Letters, 193:105-108 (1995).	
	389	KOVÁCS et al., "Mutations of the Prion Protein Gene Phenotypic Spectrum," J. Neurol., 249:1567-1582 (2002).	
	259	LANSBURY, PETER T., "Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease," Curr. Ops. in Chemical Biology, 1:260-267 (1997).	
	260	LEMERE, et al., "Nasal Aβ treatment induces anti-Aβ antibody production and decreases cerebral amyloid burden in PD-APP mice," Annals of the NY Acad. Sci., 920:328-331 (2000).	
	261	MAK, et al., "Polyclonals to b-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum," Brain Research, 667:138-142 (1994).	
	263	MANN, et al., "Amyloid β protein (Aβ) deposition in chromosome 14-linked Alzheimer's disease: Predominance of $Aβ_{42(43)}$," Annals of Neurology, 40:149-156 (1996).	
	262	MANN, et al., "The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype," Neuroscience Letters, 196:105-108 (1995).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 9

Complete if Known	
Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Sharon L. Turner
Attorney Docket Number	15270J-004740US

	264	MCGEER, et al., "Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy," J. of Neuroscience Res., 31:428-442 (1992).
	238	MCNEAL et al., "Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21," Virology, 243:158-166 (1998).
	265	MENA, et al., "Monitoring pathological assembly of tau and β-amyloid proteins in Alzheimer's disease," Acta Neuropathol., 89:50-56 (1995).
	367	MONSONEGO et al., "Immune hyporesponsiveness to amyloid β-peptide in amyloid precursor protein transgenic mice: Implications for the pathogenesis and treatment of Alzheimer's disease," PNAS, 98(18):10273-10278 (2001).
	233	MORRIS, et al., "The Consortium to Establish a registry for Alzheimer's Disease (CERAD)," Neurology, 39:1159-65 (1989).
	250	NAKAMURA et al., "Histopathological studies on senile plaques and cerebral amyloid angiopathy in aged cynomologus monkeys," Exp. Anim., 43:711-718 (1995).
	268	NAKAMURA, et al., "Carboxyl end-specific monoclonal antibodies to amyloid β protein (Aβ) subtypes (Aβ40 and Aβ42(43) differentiate Ab in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys," Neuroscience Letters, 201:151-154 (1995).
	281	NAKAYAMA et al., "Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys," J. of Med. Primatology, 27:244-252 (1998).
	235	NEWCOMBE and COHEN, "Solubility characteristics of isolated amyloid fibrils," Biochim. Biophys. Acta, 104:480-486 (1965).
	398	PALHA et al., "Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidiotic polyneuropathy, " J. Mol. Med., 7:703-707 (2001).
	406	PAN et al., "Antibodies to β-Amyloid Decrease the Blood-to-Brain Transfer of β-Amyloid Peptide," Exp. Biol. Med., 227(8):609-615 (2002).
	280	PARDRIDGE et al., "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," Biochem. Biophys. Res. Comm., 146:307-313 (1987).
	232	PETERSON, et al., "Recombinant Antibodies: Alternative Strategies for Developing and Manipulating Murine-Derived Monoclonal Antibodies," Laboratory Animal Science, 46(1):8-14 (1996).

Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 9

Complete if Known	
Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Sharon L. Turner
Attorney Docket Number	15270J-004740US

	269	PHILIPPE, et al. "Generation of a monoclonal antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amyloid precursor protein," J. of Neuroscience Res., 46:709-719 (1996).
	394	PRUSINER et al., "Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies," PNAS, 90:10608-10612 (1993).
	279	SAITO et al., "Vector-mediated delivery of ^{125}I-labeled β-amyloid peptide Ab$^{1-40}$ through the blood-brain barrier and binding to Alzheimer disease amyloid of the Aβ^{1-40} vector complex," PNAS USA, 92:10227-10231 (1995).**
	278	SAITOH, N. et al., "Immunological analysis of Alzheimer's disease using anti- β-protein monoclonal antibodies," Sapporo Med. J., 60:309-320 (1991).
	277	SASAKI et al., "Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study," Brain Res., 755:193-201 (1997).
	270	SCHENK, et al., "β-peptide immunization," Arch. Neurol., 57:934-936 (2000).
	396	SIGURDSSON et al., "Anti-priori antibodies for prophylaxis following prion exposure in mice," Neurosciences Letters, 336:185-187 (2003).
	384	SIGURDSSON et al., "Immunization Delays the Onset of Prion Disease in Mice," American Journal of Pathology, 161:13-17 (2002).
	400	SIGURDSSON et al., "A safer vaccine for Alzheimer's disease?," Neurobiology of Aging, 23:1001-1008 (2002).
	368	SIPE, "Amyloidosis," Annu. Rev. Biochem., 61:947-975 (1992).
	369	SPOONER et al., "The generation and characterization of potentially therapeutic Aβ antibodies in mice: differences according to strain and immunization protocol," Vaccine, 21:290-297 (2002).
	271	ST. GEORGE-HYSLOP et al., "Antibody clears senile plaques," Nature, 40:116-117 (1999).
	361	SU et al., "Intravascular infusions of soluble β-amyloid compromise the blood-brain barrier, activate CNS Glial cells and induce peripheral hemorrhage," Brain Research, 818:105-107 (1999).
	272	SZENDREI, et al., "The effects of aspartic acid-bond isomerization on in vitro properties of the amyloid β-peptide as modeled with N-terminal decapeptide fragments," Int. J. Peptide Protein Res., 47:289-296 (1996).

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 9

Complete if Known	
Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Sharon L. Turner
Attorney Docket Number	15270J-004740US

	392	TAL et al., "Complete Freund's Adjuvant Immunization Prolongs Survival in Experimental Prion Disease in Mice," Journal of Neuroscience Research, 71:286-290 (2003).	
	399	TAN et al., "Amyloidosis," Histopathology, 25:403-414 (1994).	
	273	THORSETT, E.D. et al., "Therapeutic approaches to Alzheimer's disease," Curr. Op. in Chem. Biology, 4:377-382 (2000).	
	276	TJERNBERG et al., "Arrest of β-amyloid fibril formation by a pentapeptide ligand," Journal of Biological Chemistry, 271:8545-8548 (1996).	
	375	TSUZUKI et al., "Amyloid β protein in rat soleus in choroquine-induced myopthy using end-specific antibodies for Aβ40 and Aβ42: immunohistochemical evidence for amyloid β protein," Neuroscience Letters, 2002:77-80 (1995).	
	274	WEINER et al., "Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," Annals of Neurology, 48:567-579 (2000).	
	387	WELDON et al., "Neurotoxicity of Aβ Peptide: Confocal Imaging of Cellular Changes Induced by – Amyloid in Rat CNS *In Vivo*," Society for Neuroscicence Abstracts, 22(Part 1) (1996). ****	
	223	WISCONSIN ALUMNI RESEARCH FOUNDATION, "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals", U.S. Govt. Res. Develop. Rep., 70(24), 56. (Publication date unknown.)	
	385	WISNIEWSKI et al., "Therapeutics in Alzheimer's and Prion Diseases," Biochemical Society Transactions, 30(4):-574-587 (2002).	
	275	WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997).	
	292	YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," Acta Neuropathol., 95:217-222 (1998).	
	290	YOUNKIN, "Amyloid β vaccination: reduced plaques and improved cognition," Nature Medicine, 7:18-19 (2001).	

Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

On August 25, 2000

TOWNSEND and TOWNSEND and CREW LLP

By: Chr Fatting

PATENT
Attorney Docket No.: 15270J-004740US
Client Reference No.: 00209-US-CIP5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Dale B. Schenk

Application No.: 09/322,289

Filed: May 28, 1999

For: PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE

Examiner: Unassigned

Art Unit: 1648

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97 and §1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. Applicant's draw Examiner's attention to related US application Nos. 09/201,430 filed November 30, 1998 and 09/204,838, filed December 3, 1998. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and

no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Joe Liebeschuetz
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
JOL:crf

PA 3071923 v1

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Attorney Docket No.: 15270-004740US	Application No.: 09/322,289
	Applicant: Dale B. Schenk	
	Filing Date: May 28, 1999	Group: 1648

Reference Designation — **U.S. PATENT DOCUMENTS** — Page 1

Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
_____ AA	5,955,317	9/21/99	Suzuki et al.			
_____ AB	5,955,079	9/21/99	Mond et al.			
_____ AC	5,869,093	2/9/99	Weiner et al.			
_____ AD	5,869,054	2/9/99	Weiner et al.			
_____ AE	5,854,204	12/29/98	Findeis et al.			
_____ AF	5,849,298	12/15/98	Weiner et al.			
_____ AG	5,786,180	7/28/98	Konig et al.			
_____ AH	5,750,349	5/12/98	Suzuki et al.			
_____ AI	5,733,547	3/31/98	Weiner et al.			
_____ AJ	5,688,651	11/18/97	Solomon			
_____ AK	5,645,820	7/8/97	Hafler et al.			
_____ AL	5,641,474	6/24/97	Hafler et al.			
_____ AM	5,641,473	6/24/97	Hafler et al.			
_____ AN	5,585,100	12/17/96	Mond et al.			
_____ AO	5,571,500	11/5/96	Hafler et al.			
_____ AP	5,571,499	11/5/96	Hafler et al.			
_____ AQ	5,434,170	7/18/95	Andrulis et al.			
_____ AR	5,387,742	2/7/95	Cordell			
_____ AS	5,231,000	7/27/93	Majocha et al.			
_____ AT	5,192,753	3/9/93	McGeer et al.			

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
_____ AU	WO 99/60024	11/25/99	PCT			
_____ AV	WO 99/60021	11/25/99	PCT			
_____ AW	WO 99/58564	11/18/99	PCT			
_____ AX	WO 99/27949	6/10/99	PCT			
_____ AY	WO 99/06066	2/11/99	PCT			
_____ AZ	WO 96/39176	12/12/96	PCT			
_____ BA	WO 96/25435	8/22/96	PCT			
_____ BB	WO 96/18900	6/20/96	PCT			
_____ BC	WO 95/31996	11/30/95	PCT			
_____ BD	WO 95/04151	2/9/95	PCT			
_____ BE	WO 94/03615	2/17/94	PCT			
_____ BF	WO 93/21950	11/11/93	PCT			
_____ BG	WO 93/16724	9/2/93	PCT			

4/25/00

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			Attorney Docket No.: 15270-004740US		Application No.: 09/322,289	
			Applicant: Dale B. Schenk			
			Filing Date: May 28, 1999		Group: 1648	
_____ BH	WO 93/15760	8/19/93	PCT			
_____ BI	WO 93/14200	7/22/93	PCT			
_____ BJ	WO 93/02189	2/4/93	PCT			
_____ BK	WO 92/06708	4/30/92	PCT			
_____ BL	WO 92/06187	4/16/92	PCT			
_____ BM	WO 91/19810	12/26/91	PCT			
_____ BN	WO 91/16819	11/14/91	PCT			
_____ BO	WO 91/12816	9/5/91	PCT			
_____ BP	WO 91/08760	6/27/91	PCT			
_____ BQ	WO 90/12871	11/1/90	PCT			
_____ BR	WO 90/12870	11/1/90	PCT			
_____ BS	WO 89/06242	7/13/89	PCT			
_____ BT	WO 89/06689	7/27/89	PCT			
_____ BU	WO 88/10120	12/29/88	PCT			
_____ BV	EP 506 785	3/15/00	Europe			
_____ BW	EP 639 081	11/3/99	Europe			
_____ BX	EP 561 087	8/4/99	Europe			
_____ BY	EP 911 036	4/28/99	Europe			
_____ BZ	EP 652 962	12/16/98	Europe			
_____ CA	EP 863 211	9/9/98	Europe			
_____ CB	EP 845 270	6/3/98	Europe			
_____ CC	EP 594 607	8/27/97	Europe			
_____ CD	EP 782 859	7/9/97	Europe			
_____ CE	EP 440 619	1/24/96	Europe			
_____ CF	EP 359 783	11/29/95	Europe			
_____ CG	EP 683 234	11/22/95	Europe			
_____ CH	EP 666 080	8/9/95	Europe			
_____ CI	EP 451 700	10/16/91	Europe			
_____ CJ	GB 2 335 192	9/15/99	United Kingdom			

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

_____ CK	Andersen et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?," Neurology, 45:1441-1445 (1995).
_____ CL	Associated Press, "Immune cells may promote Alzehimer's, a study finds," *The Boston Globe* (4/13/95).
_____ CM	Bauer et al., "Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," FEBS Letters, 285(1):111-114 (1991).
_____ CN	Bodmer et al., "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," Biochem. Biophys. Res. Comm., 171(2):890-897 (1990).
_____ CO	Blass, John P., "Immunologic Treatment of Alzheimer's Disease," New England J. Medicine, 341(22):1694 (1999).

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Attorney Docket No.: 15270-004740US	Application No.: 09/322,289
	Applicant: Dale B. Schenk	
	Filing Date: May 28, 1999	Group: 1648

_____ CP	Brice et al., "Absense of the amyloid precursor protein gene mutation (APP717 : Val->Ile) in 85 cases of early onset Alzheimer's disease," J. Neurology, Neurosurg. Psychiatry, 56:112-115 (1993).
_____ CQ	Chao et al., "Transforming Growth Factor-β Protects human Neurons Against β-Amyloid-Induced Injury," Soc. Neurosci. Abstracts, 19:513.7 (1993).
_____ CR	Felsenstein et al., "Processing of the β-amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," Neuroscience Letters, 152:185-189 (1993).
_____ CS	Finch et al., "Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease," Neurobiology of Aging, 17(5):809-815 (1996).
_____ CT	Fisher et al., "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," PNAS, 88:1779-1782 (1991).
_____ CU	Flanders et al., "Altered expression of transforming growth factor-β in Alzheimer's disease," Neurology, 45:1561-1569 (1995).
_____ CV	Gandy et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," TiPS, 13:108-113 (1992).
_____ CW	Goate et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," Nature, 349:704-706 (1991).
_____ CX	Gozes et al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," PNAS, 93:427-432 (1996).
_____ CY	Haga et al., "Synthetic Alzheimer amyloid β/A4 peptides enhance production of complement C3 component by cultured microglial cells," Brain Research, 601:88-94 (1993).
_____ CZ	Hardy, John, "New Insights into the Genetics of Alzheimer's Disease," Annals of Med., 28:255-258 (1996).
_____ DA	Huberman et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," J. Neuroimmunology, 52:147-152 (1994).
_____ DB	Hyman et al., "Molecular Epidemiology of Alzheimer's Disease," N. E. J. Medicine, 333(19):1283-1284 (1995).
_____ DC	Itagaki et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," J. Neuroimmunology, 24:173-182 (1989).
_____ DD	Kalaria, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," Res. Immunology, 143:637-641 (1992).
_____ DE	Kawabata et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," Nature, 354:476-478 (1991).
_____ DF	Lampert-Etchells et al., "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," Neurodegeneration, 2:111-121 (1993).
_____ DG	Lannfelt et al., "Alzheimer's disease: molecular genetics and transgenic animal models," Behavioural Brain Res., 57:207-213 (1993).
_____ DH	Meda et al., "Activation of microglial cells by β-amyloid protein and interferon-γ," Nature, 374:647-650 (1995).
_____ DI	Miller et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," J. Exp. Med., 174:791-798 (1991).
_____ DJ	New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94).
_____ DK	Quon et al., "Formation of β-Amyloid protein deposits in brains of transgenic mice," Nature, 352:239-241 (1991).
_____ DL	Rogers et al., "Complement activation by β-amyloid in Alzheimer Disease," PNAS, 89:1-5 (1992).
_____ DM	Rossor et al., "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," Annals of New York Academy of Sciences, 695:198-202 (1993).
_____ DN	Selkoe, Dennis J., "Amyloid Protein and Alzheimer's Disease……," Scientific American, pgs. 68-78 (11/91).
_____ DO	Selkoe, Dennis J., "In the Beginning…," Nature, 354:432-433 (1991).
_____ DP	Selkoe, Dennis J., "The Molecular pathology of Alzheimer's Disease," Neuron, 6:487-498 (1991).

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Attorney Docket No.: 15270-004740US	Application No.: 09/322,289
	Applicant: Dale B. Schenk	
	Filing Date: May 28, 1999	Group: 1648

_____ DQ	Selkoe, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," Science, 275:630-631 (1997).
_____ DR	Shiosaka, Sadao, "Attempts to make models for Alzheimer's disease," Neuroscience Res., 13:237-255 (1992).
_____ DS	Solomon, B., "New Approach Towards Fast Induction of Anti β-Amyloid Peptide Immune Response," Department of Molecular Microbiology & Biotechnology, Tel-Aviv University, ramat Aviv, Tel-Aviv, Israel.
_____ DT	Tanaka et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," European J. Pharmacology, 352:135-142 (1998).
_____ DU	Trieb et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," Immunobiology, 191(2-3):114-115 Abstract C.37, (1994).
_____ DV	Verbeek et al., "Accumulation of Intercellular Adheasion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," Amer. Journ. Pathology, 144(1):104-116 (1994).
_____ DW	Walker et al., "Labeling of Cerebral Amyloid *In Vivo* with a Monoclonal Antibody," J. Neuropath. Exp. Neurology, 53(4):377-383 (1994).
_____ DX	Weiner et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," Annu. Rev. Immunol., 12:809-837 (1994).
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Attorney Docket No.: 15270-004740US	Application No.: 09/322,289
	Applicant: Dale B. Schenk	
	Filing Date: May 28, 1999	Group: 1648

Reference Designation — **U.S. PATENT DOCUMENTS** — Page 1

Examiner Initial		Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
	3	5,955,317	9/21/99	Suzuki et al.			
	4	5,955,079	9/21/99	Mond et al.			
	6	5,869,093	2/9/99	Weiner et al.			
	7	5,869,054	2/9/99	Weiner et al.			
	8	5,854,204	12/29/98	Findeis et al.			
	10	5,849,298	12/15/98	Weiner et al.			
	12	5,786,180	7/28/98	Konig et al.			
	14	5,750,349	5/12/98	Suzuki et al.			
	15	5,733,547	3/31/98	Weiner et al.			
	16	5,688,651	11/18/97	Solomon			
	18	5,645,820	7/8/97	Hafler et al.			
	19	5,641,474	6/24/97	Hafler et al.			
	20	5,641,473	6/24/97	Hafler et al.			
	23	5,585,100	12/17/96	Mond et al.			
	24	5,571,500	11/5/96	Hafler et al.			
	25	5,571,499	11/5/96	Hafler et al.			
	26	5,434,170	7/18/95	Andrulis et al.			
	27	5,387,742	2/7/95	Cordell			
	28	5,231,000	7/27/93	Majocha et al.			
	31	5,192,753	3/9/93	McGeer et al.			

FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
	53	WO 99/60024	11/25/99	PCT			
	54	WO 99/60021	11/25/99	PCT			
	55	WO 99/58564	11/18/99	PCT			
	57	WO 99/27949	6/10/99	PCT			
	56	WO 99/06066	2/11/99	PCT			
	63	WO 96/39176	12/12/96	PCT			
	64	WO 96/25435	8/22/96	PCT			
	65	WO 96/18900	6/20/96	PCT			
	66	WO 95/31996	11/30/95	PCT			
	70	WO 95/04151	2/9/95	PCT			
	71	WO 94/03615	2/17/94	PCT			
	73	WO 93/21950	11/11/93	PCT			
	74	WO 93/16724	9/2/93	PCT			

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Attorney Docket No.: 15270-004740US	Application No.: 09/322,289
	Applicant: Dale B. Schenk	
	Filing Date: May 28, 1999	Group: 1648

	75	WO 93/15760	8/19/93	PCT			
	76	WO 93/14200	7/22/93	PCT			
	77	WO 93/02189	2/4/93	PCT			
	79	WO 92/06708	4/30/92	PCT			
	80	WO 92/06187	4/16/92	PCT			
	81	WO 91/19810	12/26/91	PCT			
	82	WO 91/16819	11/14/91	PCT			
	83	WO 91/12816	9/5/91	PCT			
	84	WO 91/08760	6/27/91	PCT			
	85	WO 90/12871	11/1/90	PCT			
	86	WO 90/12870	11/1/90	PCT			
	88	WO 89/06242	7/13/89	PCT			
	89	WO 89/06689	7/27/89	PCT			
	91	WO 88/10120	12/29/88	PCT			
	48	EP 506 785	3/15/00	Europe			
	43	EP 639 081	11/3/99	Europe			
	46	EP 561 087	8/4/99	Europe			
	35	EP 911 036	4/28/99	Europe			
	42	EP 652 962	12/16/98	Europe			
	37	EP 863 211	9/9/98	Europe			
	38	EP 845 270	6/3/98	Europe			
	45	EP 594 607	8/27/97	Europe			
	39	EP 782 859	7/9/97	Europe			
	50	EP 440 619	1/24/96	Europe			
	51	EP 359 783	11/29/95	Europe			
	40	EP 683 234	11/22/95	Europe			
	41	EP 666 080	8/9/95	Europe			
	49	EP 451 700	10/16/91	Europe			
	93	GB 2 335 192	9/15/99	United Kingdom			

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	94	Andersen et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?," Neurology, 45:1441-1445 (1995).
	95	Associated Press, "Immune cells may promote Alzehimer's, a study finds," *The Boston Globe* (4/13/95).
	96	Bauer et al., "Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," FEBS Letters, 285(1):111-114 (1991).
	98	Bodmer et al., "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," Biochem. Biophys. Res. Comm., 171(2):890-897 (1990).
	97	Blass, John P., "Immunologic Treatment of Alzheimer's Disease," New England J. Medicine, 341(22):1694 (1999).

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Attorney Docket No.: 15270-004740US	Application No.: 09/322,289
	Applicant: Dale B. Schenk	
	Filing Date: May 28, 1999	Group: 1648

_____	101	Brice et al., "Absense of the amyloid precursor protein gene mutation (APP717 : Val->Ile) in 85 cases of early onset Alzheimer's disease," J. Neurology, Neurosurg. Psychiatry, 56:112-115 (1993).
_____	102	Chao et al., "Transforming Growth Factor-β Protects human Neurons Against β-Amyloid-Induced Injury," Soc. Neurosci. Abstracts, 19:513.7 (1993).
_____	105	Felsenstein et al., "Processing of the β-amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," Neuroscience Letters, 152:185-189 (1993).
_____	106	Finch et al., "Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease," Neurobiology of Aging, 17(5):809-815 (1996).
_____	107	Fisher et al., "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," PNAS, 88:1779-1782 (1991).
_____	108	Flanders et al., "Altered expression of transforming growth factor-β in Alzheimer's disease," Neurology, 45:1561-1569 (1995).
_____	110	Gandy et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," TiPS, 13:108-113 (1992).
_____	115	Goate et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," Nature, 349:704-706 (1991).
_____	116	Gozes et al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," PNAS, 93:427-432 (1996).
_____	118	Haga et al., "Synthetic Alzheimer amyloid β/A4 peptides enhance production of complement C3 component by cultured microglial cells," Brain Research, 601:88-94 (1993).
_____	121	Hardy, John, "New Insights into the Genetics of Alzheimer's Disease," Annals of Med., 28:255-258 (1996).
_____	123	Huberman et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," J. Neuroimmunology, 52:147-152 (1994).
_____	124	Hyman et al., "Molecular Epidemiology of Alzheimer's Disease," N. E. J. Medicine, 333(19):1283-1284 (1995).
_____	125	Itagaki et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," J. Neuroimmunology, 24:173-182 (1989).
_____	127	Kalaria, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," Res. Immunology, 143:637-641 (1992).
_____	128	Kawabata et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," Nature, 354:476-478 (1991).
_____	29	Lampert-Etchells et al., "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," Neurodegeneration, 2:111-121 (1993).
_____	131	Lannfelt et al., "Alzheimer's disease: molecular genetics and transgenic animal models," Behavioural Brain Res., 57:207-213 (1993).
_____	136	Meda et al., "Activation of microglial cells by β-amyloid protein and interferon-γ," Nature, 374:647-650 (1995).
_____	137	Miller et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," J. Exp. Med., 174:791-798 (1991).
_____	139	New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94).
_____	143	Quon et al., "Formation of β-Amyloid protein deposits in brains of transgenic mice," Nature, 352:239-241 (1991).
_____	146	Rogers et al., "Complement activation by β-amyloid in Alzheimer Disease," PNAS, 89:1-5 (1992).
_____	147	Rossor et al., "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," Annals of New York Academy of Sciences, 695:198-202 (1993).
_____	152	Selkoe, Dennis J., "Amyloid Protein and Alzheimer's Disease……," Scientific American, pgs. 68-78 (11/91).
_____	153	Selkoe, Dennis J., "In the Beginning…," Nature, 354:432-433 (1991).
_____	154	Selkoe, Dennis J., "The Molecular pathology of Alzheimer's Disease," Neuron, 6:487-498 (1991).

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Attorney Docket No.: 15270-004740US	Application No.: 09/322,289
	Applicant: Dale B. Schenk	
	Filing Date: May 28, 1999	Group: 1648

[redacted] 155	Selkoe, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," Science, 275:630-631 (1997).
[redacted] 157	Shiosaka, Sadao, "Attempts to make models for Alzheimer's disease," Neuroscience Res., 13:237-255 (1992).
[redacted] 162	Solomon, B., "New Approach Towards Fast Induction of Anti β-Amyloid Peptide Immune Response," Department of Molecular Microbiology & Biotechnology, Tel-Aviv University, ramat Aviv, Tel-Aviv, Israel.
[redacted] 165	Tanaka et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," European J. Pharmacology, 352:135-142 (1998).
[redacted] 166	Trieb et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," Immunobiology, 191(2-3):114-115 Abstract C.37, (1994).
[redacted] 168	Verbeek et al., "Accumulation of Intercellular Adheasion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," Amer. Journ. Pathology, 144(1):104-116 (1994).
[redacted] 169	Walker et al., "Labeling of Cerebral Amyloid *In Vivo* with a Monoclonal Antibody," J. Neuropath. Exp. Neurology, 53(4):377-383 (1994).
[redacted] 171	Weiner et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," Annu. Rev. Immunol., 12:809-837 (1994).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.